Related Experiment Video
Updated: May 31, 2025
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Hepatitis C Virus-Pediatric and Adult Perspectives in the Current Decade
1Massachusetts General Brigham for Children, 175 Cambridge Street, Boston, MA 02114, USA.
Insights
Hepatitis C virus (HCV) infection affects all ages, with direct-acting antivirals offering a cure. New technologies may advance understanding, but an HCV vaccine is still needed for global elimination.
Area of Science:
- Hepatology
- Virology
- Public Health
Background:
- Hepatitis C virus (HCV) is a significant global cause of chronic liver disease in both children and adults.
- Differences exist in screening and management protocols for pediatric versus adult HCV patients.
- HCV can lead to severe liver complications like cirrhosis, cancer, and the need for transplantation, even in rare pediatric cases.
Purpose of the Study:
- To review the current landscape of Hepatitis C virus (HCV) infection, focusing on pediatric and adult populations.
- To highlight challenges and advancements in HCV screening, management, and treatment.
- To explore emerging technologies that could enhance understanding and treatment of HCV.
Main Methods:
- Review of current literature on HCV epidemiology, treatment, and emerging technologies.
- Comparison of pediatric and adult HCV management strategies.
- Discussion of novel research tools such as artificial intelligence, machine learning, liver organoids, and liver-on-chip models.
Main Results:
- Direct-acting antiviral agents (DAAs) have made HCV curable and are approved for ages three and up, though pediatric treatment presents unique challenges.
- The World Health Organization aims to eliminate HCV by 2030, but it remains a global health burden.
- Advanced technologies like AI and organoids show promise for improving HCV research and understanding.
Conclusions:
- HCV cure is achievable with DAAs, but challenges remain, particularly in pediatric populations.
- Despite progress, a widely available HCV vaccine has not yet been developed, hindering global elimination efforts.
- Emerging technologies offer new avenues for research and potentially improved strategies against HCV.
Abstract:
Hepatitis C virus (HCV) infects both pediatric and adult populations and is an important cause of chronic liver disease worldwide. There are differences in the screening and management of HCV between pediatric and adult patients, which have been highlighted in this review. Direct-acting antiviral agents (DAA) have made the cure of HCV possible, and fortunately, these medications are approved down to three years of age. However, treatment in the pediatric population has its own set of challenges. The World Health Organization (WHO) has made a pledge to eliminate HCV as a public health threat by 2030. Despite this, HCV continues to remain a global health burden, leading to cirrhosis as well as hepatocellular carcinoma, and is a reason for liver transplantation in the adult population. Although rare, these complications can also affect the pediatric population. A variety of new technologies t have become available in the current era and can advance our understanding of HCV are discussed. Artificial intelligence, machine learning, liver organoids, and liver-on-chip are some examples of techniques that have the potential to contribute to our understanding of the disease and treatment process in HCV. Despite efforts over several decades, a successful vaccine against HCV has yet to be developed. This would be an important tool to help in worldwide efforts to eliminate the virus.
Related Concept Videos
01:10Retrovirus Life Cycles
01:25Immunodeficiency Diseases
There are three main causes of immunodeficiency...
02:33Retroviruses